Merck to Develop Global GLP-1 Receptor Agonist with Hansoh Pharma
Merck (MSD outside of the US and Canada) has entered into an exclusive global license agreement with Chinese biopharmaceutical company Hansoh Pharma for its investigational oral GLP-1 receptor agonist, HS-10535. The deal grants Merck rights to develop, manufacture, and commercialize the compound, while Hansoh Pharma will receive an upfront payment of $112 million and up … Read more